Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR17003-25] to MMP2
- Suitable for: WB, IP
- Reacts with: Mouse, Rat, Human
Product nameAnti-MMP2 antibody [EPR17003-25]
See all MMP2 primary antibodies
DescriptionRabbit monoclonal [EPR17003-25] to MMP2
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Mouse, Rat, Human
Recombinant fragment within Mouse MMP2 aa 100-300. The exact sequence is proprietary.
Database link: P33434
- IP: HT1080 whole cell lysate. WB: Human, mouse and rat plasma lysates; Rat serum lysate; Mouse and rat lung lysates; HT1080 whole cell lysate.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab181286 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 74 kDa (predicted molecular weight: 73 kDa).|
FunctionUbiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-
-Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro.
PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels.
Tissue specificityProduced by normal skin fibroblasts. PEX is expressed in a number of tumors including gliomas, breast and prostate.
Involvement in diseaseDefects in MMP2 are the cause of Torg-Winchester syndrome (TWS) [MIM:259600]; also known as multicentric osteolysis nodulosis and arthropathy (MONA). TWS is an autosomal recessive osteolysis syndrome. It is severe with generalized osteolysis and osteopenia. Subcutaneous nodules are usually absent. Torg-Winchester syndrome has been associated with a number of additional features including coarse face, corneal opacities, patches of thickened, hyperpigmented skin, hypertrichosis and gum hypertrophy. However, these features are not always present and have occasionally been observed in other osteolysis syndromes.
Sequence similaritiesBelongs to the peptidase M10A family.
Contains 3 fibronectin type-II domains.
Contains 4 hemopexin-like domains.
DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
modificationsPhosphorylation on multiple sites modulates enzymatic activity. Phosphorylated by PKC in vitro.
The propeptide is processed by MMP14 (MT-MMP1) and MMP16 (MT-MMP3). Autocatalytic cleavage in the C-terminal produces the anti-angiogenic peptide, PEX. This processing appears to be facilitated by binding integrinv/beta3.
Cellular localizationSecreted > extracellular space > extracellular matrix. Membrane. Nucleus. Colocalizes with integrin alphaV/beta3 at the membrane surface in angiogenic blood vessels and melanomas. Found in mitochondria, along microfibrils, and in nuclei of cardiomyocytes.
- Information by UniProt
- 72 kDa gelatinase antibody
- 72kD type IV collagenase antibody
- CLG 4 antibody
MMP2 was immunoprecipitated from 0.35 mg HT1080 (human fibrosarcoma cell line) whole cell lysate with ab181286 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab181286 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.
Lane 1: HT1080 whole cell lysate 10 µg (Input).
Lane 2: ab181286 IP in HT1080 whole cell lysate (+).
Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab181286 in HT1080 whole cell lysate (-).
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
Lanes 1-5 : Anti-MMP2 antibody [EPR17003-25] (ab181286) at 1/1000 dilution
Lanes 6-7 : Anti-MMP2 antibody [EPR17003-25] (ab181286) at 1/2000 dilution
Lane 1 : Mouse plasma lysate at 20 µg
Lane 2 : Rat serum lysate at 20 µg
Lane 3 : Mouse lung lysate at 20 µg
Lane 4 : Rat plasma lysate at 20 µg
Lane 5 : Rat lung lysate at 20 µg
Lane 6 : HT1080 (human fibrosarcoma cell line) whole cell lysate at 10 µg
Lane 7 : Human plasma lysate at 10 µg
All lanes : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/10000 dilution
Predicted band size: 73 kDa
Observed band size: 72 kDa why is the actual band size different from the predicted?
Exposure time: Lanes 1-2: 3 minutes; Lanes 3-5: 10 seconds; Lanes 6-7: 30 seconds.
Blocking/Dilution buffer: 5% NFDM/TBST.
ab181286 has been referenced in 2 publications.